by Mybiogate | Sep 18, 2020 | Industry Research
Author: Ginger Ding The rate of return on investment in new drugs has steadily declined; it is imperative to improve R&D efficiency New drug research and development has three characteristics that may raise concerns: high cost (985.3 million [1]), a long... by Mybiogate | Sep 17, 2020 | Industry Research
Author: Ginger Ding On September 4, 2020, I-Mab Biopharma announced a collaboration with AbbVie on the global development and commercialization of CD47 monoclonal antibody TJC4. The US$2.9 billion collaboration signifies the largest out-licensing in the history... by Mybiogate | Sep 16, 2020 | Industry Research
The global pediatric drug market has steady growth with China ranking second The global pediatric drug and vaccine market was valued at approximately US$122 billion in 2019. By 2025 it is expected to reach US$141 billion, with a compound annual growth rate of 2.4%. At... by Mybiogate | Sep 15, 2020 | Industry Research
Ginger Ding, Chen Lixing Introduction “Industry Research | Pediatric Drug Market and Cross-border Collaboration Trends (Part 1)” reviews the latest legislation and incentive measures that aim to promote the development of the pediatric... by Mybiogate | Sep 14, 2020 | Industry Research
Ginger Ding, Chen Lixing Introduction Children ages 0 to 18 account for about 26% of the global population, but the development and market value of pediatric drugs has been seriously underrepresented for a long time. Due to the gradual implementation of the... by Mybiogate | Sep 3, 2020 | Industry Research
Gradual increases in Chinese residents’ disposable income, more people undergoing plastic surgery at younger ages, and the aging population have exacerbated consumer expansion for plastic microsurgeries. According to statistics from the Health Commission, the total...